Investment
Features
FeesSafety
Academy
More
Pluang+

Mobile money frameworks are key to stablecoin regulation, says Circle, citing Africa's M-Pesa success.

Market News
10 Jul 2026
Crypto Briefing
View Source
Bullish
Mobile money frameworks are key to stablecoin regulation, says Circle, citing Africa's M-Pesa success.

Circle argues that countries with established mobile money systems, like Kenya's M-Pesa, are well-positioned to regulate stablecoins effectively. Their Internet Financial System Report suggests stablecoins should be seen as an evolution of electronic money, not a new financial experiment. Circle highlights the EU's MiCA framework as a successful regulatory model, noting their euro stablecoin EURC's rapid adoption under MiCA. Partnerships in Africa aim to integrate USDC with mobile wallets, facilitating cross-border payments and boosting financial inclusion. This approach positions USDC as a stablecoin favored by regulators, with growing on-chain activity and wallet use.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
1 hour ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
2 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex to report Q1 2027 earnings with expected EPS of $1.32 and $1.63B revenue on Sept 23

Paychex, a provider of human capital management solutions, will release its Q1 fiscal 2027 earnings on September 23, 2026. Analysts expect earnings per share (EPS) of $1.32, up from $1.22 last year, and revenue of about $1.63 billion, higher than las...

Company Fundamentals
Bullish
4 hours ago
Semiconductor ETFs remain strong buys amid AI-driven demand and investment growth.

Semiconductor ETFs remain strong buys amid AI-driven demand and investment growth.

iShares Semiconductor ETF and VanEck Semiconductor ETF are recommended as strong buys due to robust capital investment driven by AI infrastructure and sector demand outpacing the broader market. The AI buildout is attracting unprecedented capital int...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App